New chemotherapy agents for small cell lung cancer

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Background: Approximately 45,000 new cases of small cell lung cancer (SCLC) will be diagnosed in the United States this year. Combination chemotherapy is the cornerstone of treatment for all stages of this disease and results in high response rates (65 to 85%), leading to a meaningful survival advantage for these patients. Patients with limited-stage disease enjoy a median survival of 10 to 15 months with chemotherapy, as compared to 3 months without drug therapy. With addition of chest radiotherapy, survival is further prolonged to 12 to 20 months. Patients with extensive-stage disease experience an average survival of 1.5 months without chemotherapy and 7 to 11 months with chemotherapy. However, no further improvement in survival has been demonstrated since combination chemotherapy regimens were introduced in the late 1970s and early 1980s, despite evaluating numerous strategies; the 5-year survival for all patients remains dismal at 5%. Clearly, new chemotherapy agents with novel mechanisms of action are needed. Focus: This article will review the experience to date with six new agents that are active against SCLC. It includes two taxanes (paclitaxel and docetaxel), vinorelbine, two camptothecin derivatives (topotecan and irinotecan), and gemcitabine. Single-agent activity as well as combination regimens with other agents and radiotherapy will be discussed. The role of maintenance therapy with oral matrix metalloproteinase inhibitors also is evaluated.

Original languageEnglish (US)
JournalChest
Volume117
Issue number4 SUPPL. 1
StatePublished - 2000
Externally publishedYes

Fingerprint

Small Cell Lung Carcinoma
Drug Therapy
Survival
irinotecan
docetaxel
gemcitabine
Combination Drug Therapy
Radiotherapy
Topotecan
Taxoids
Camptothecin
Matrix Metalloproteinase Inhibitors
Paclitaxel
Thorax
Therapeutics

Keywords

  • Carboplatin
  • Cisplatin
  • Gemcitabine
  • Small cell lung cancer
  • Survival
  • Taxanes
  • Topotecan
  • Vinorelbine

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

New chemotherapy agents for small cell lung cancer. / Kelly, Karen.

In: Chest, Vol. 117, No. 4 SUPPL. 1, 2000.

Research output: Contribution to journalArticle

@article{e391bfc8ea4b4c7b99a21bd6dcbfbfce,
title = "New chemotherapy agents for small cell lung cancer",
abstract = "Background: Approximately 45,000 new cases of small cell lung cancer (SCLC) will be diagnosed in the United States this year. Combination chemotherapy is the cornerstone of treatment for all stages of this disease and results in high response rates (65 to 85{\%}), leading to a meaningful survival advantage for these patients. Patients with limited-stage disease enjoy a median survival of 10 to 15 months with chemotherapy, as compared to 3 months without drug therapy. With addition of chest radiotherapy, survival is further prolonged to 12 to 20 months. Patients with extensive-stage disease experience an average survival of 1.5 months without chemotherapy and 7 to 11 months with chemotherapy. However, no further improvement in survival has been demonstrated since combination chemotherapy regimens were introduced in the late 1970s and early 1980s, despite evaluating numerous strategies; the 5-year survival for all patients remains dismal at 5{\%}. Clearly, new chemotherapy agents with novel mechanisms of action are needed. Focus: This article will review the experience to date with six new agents that are active against SCLC. It includes two taxanes (paclitaxel and docetaxel), vinorelbine, two camptothecin derivatives (topotecan and irinotecan), and gemcitabine. Single-agent activity as well as combination regimens with other agents and radiotherapy will be discussed. The role of maintenance therapy with oral matrix metalloproteinase inhibitors also is evaluated.",
keywords = "Carboplatin, Cisplatin, Gemcitabine, Small cell lung cancer, Survival, Taxanes, Topotecan, Vinorelbine",
author = "Karen Kelly",
year = "2000",
language = "English (US)",
volume = "117",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "4 SUPPL. 1",

}

TY - JOUR

T1 - New chemotherapy agents for small cell lung cancer

AU - Kelly, Karen

PY - 2000

Y1 - 2000

N2 - Background: Approximately 45,000 new cases of small cell lung cancer (SCLC) will be diagnosed in the United States this year. Combination chemotherapy is the cornerstone of treatment for all stages of this disease and results in high response rates (65 to 85%), leading to a meaningful survival advantage for these patients. Patients with limited-stage disease enjoy a median survival of 10 to 15 months with chemotherapy, as compared to 3 months without drug therapy. With addition of chest radiotherapy, survival is further prolonged to 12 to 20 months. Patients with extensive-stage disease experience an average survival of 1.5 months without chemotherapy and 7 to 11 months with chemotherapy. However, no further improvement in survival has been demonstrated since combination chemotherapy regimens were introduced in the late 1970s and early 1980s, despite evaluating numerous strategies; the 5-year survival for all patients remains dismal at 5%. Clearly, new chemotherapy agents with novel mechanisms of action are needed. Focus: This article will review the experience to date with six new agents that are active against SCLC. It includes two taxanes (paclitaxel and docetaxel), vinorelbine, two camptothecin derivatives (topotecan and irinotecan), and gemcitabine. Single-agent activity as well as combination regimens with other agents and radiotherapy will be discussed. The role of maintenance therapy with oral matrix metalloproteinase inhibitors also is evaluated.

AB - Background: Approximately 45,000 new cases of small cell lung cancer (SCLC) will be diagnosed in the United States this year. Combination chemotherapy is the cornerstone of treatment for all stages of this disease and results in high response rates (65 to 85%), leading to a meaningful survival advantage for these patients. Patients with limited-stage disease enjoy a median survival of 10 to 15 months with chemotherapy, as compared to 3 months without drug therapy. With addition of chest radiotherapy, survival is further prolonged to 12 to 20 months. Patients with extensive-stage disease experience an average survival of 1.5 months without chemotherapy and 7 to 11 months with chemotherapy. However, no further improvement in survival has been demonstrated since combination chemotherapy regimens were introduced in the late 1970s and early 1980s, despite evaluating numerous strategies; the 5-year survival for all patients remains dismal at 5%. Clearly, new chemotherapy agents with novel mechanisms of action are needed. Focus: This article will review the experience to date with six new agents that are active against SCLC. It includes two taxanes (paclitaxel and docetaxel), vinorelbine, two camptothecin derivatives (topotecan and irinotecan), and gemcitabine. Single-agent activity as well as combination regimens with other agents and radiotherapy will be discussed. The role of maintenance therapy with oral matrix metalloproteinase inhibitors also is evaluated.

KW - Carboplatin

KW - Cisplatin

KW - Gemcitabine

KW - Small cell lung cancer

KW - Survival

KW - Taxanes

KW - Topotecan

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=0033996043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033996043&partnerID=8YFLogxK

M3 - Article

C2 - 10777472

AN - SCOPUS:0033996043

VL - 117

JO - Chest

JF - Chest

SN - 0012-3692

IS - 4 SUPPL. 1

ER -